SIMILAR PATTERN OF AMINO ACIDS MAPPED TO 'ANK'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_A_STIA201_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LYS A 82 VAL A 113 ILE A 127 MET A 132	ANK A 401 (-2.4A) None None None	1.02A	1iepA-3vn9A: 21.5	1iepA-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1IEP_B_STIB202_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 7	VAL A 113 MET A 132 ARG A 178 LEU A 186	None None None ANK A 401 ( 4.9A)	0.85A	1iepB-3vn9A: 21.7	1iepB-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1OPJ_B_STIB4_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LEU A 59 LYS A 82 ILE A 127 MET A 132	None ANK A 401 (-2.4A) None None	0.82A	1opjB-3vn9A: 21.1	1opjB-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2EVA_A_ADNA498_1 (TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 11	GLY A 60 VAL A 67 ALA A 80 MET A 129 SER A 135 LEU A 186 ASP A 197	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.77A	2evaA-3vn9A: 23.9	2evaA-3vn9A: 25.48
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_A_STIA600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LEU A 59 LYS A 82 VAL A 113 ILE A 127	None ANK A 401 (-2.4A) None None	0.84A	2hyyA-3vn9A: 22.1	2hyyA-3vn9A: 26.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_C_STIC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LEU A 59 LYS A 82 ILE A 127 MET A 132	None ANK A 401 (-2.4A) None None	0.82A	2hyyC-3vn9A: 22.2	2hyyC-3vn9A: 26.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2HYY_D_STID600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 4	LEU A 59 LYS A 82 VAL A 113 MET A 132	None ANK A 401 (-2.4A) None None	1.18A	2hyyD-3vn9A: 22.1	2hyyD-3vn9A: 26.15
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2J9C_A_ACTA1122_0 (HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 7	SER A 201 SER A 207 LYS A 210 LYS A 181	ANK A 401 (-3.6A) None ANK A 401 (-3.0A) ANK A 401 (-2.5A)	1.48A	2j9cA-3vn9A: 2.0 2j9cB-3vn9A: undetectable 2j9cC-3vn9A: 2.0	2j9cA-3vn9A: 18.13 2j9cB-3vn9A: 18.13 2j9cC-3vn9A: 18.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2J9C_A_ACTA1122_0 (HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 7	SER A 207 LYS A 210 LYS A 181 SER A 201	None ANK A 401 (-3.0A) ANK A 401 (-2.5A) ANK A 401 (-3.6A)	1.44A	2j9cA-3vn9A: 2.0 2j9cB-3vn9A: undetectable 2j9cC-3vn9A: 2.0	2j9cA-3vn9A: 18.13 2j9cB-3vn9A: 18.13 2j9cC-3vn9A: 18.13
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	2Y7J_B_B49B1294_1 (PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS/LIVER ISOFORM)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 10	VAL A 67 ALA A 80 LEU A 131 MET A 132 LEU A 186 ASP A 197	ANK A 401 (-4.3A) ANK A 401 (-3.0A) None None ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.78A	2y7jB-3vn9A: 24.1	2y7jB-3vn9A: 24.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3AOX_A_EMHA901_1 (ALK TYROSINE KINASE RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 10	LEU A 59 ALA A 80 VAL A 113 LEU A 131 MET A 132 LEU A 186	None ANK A 401 (-3.0A) None None None ANK A 401 ( 4.9A)	0.64A	3aoxA-3vn9A: 21.5	3aoxA-3vn9A: 26.24
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_A_NILA600_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 10	LEU A 59 VAL A 67 LYS A 82 VAL A 113 ILE A 127	None ANK A 401 (-4.3A) ANK A 401 (-2.4A) None None	0.68A	3cs9A-3vn9A: 21.9	3cs9A-3vn9A: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_B_NILB600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	LEU A 59 VAL A 67 LYS A 82 VAL A 113 ILE A 127	None ANK A 401 (-4.3A) ANK A 401 (-2.4A) None None	0.72A	3cs9B-3vn9A: 22.0	3cs9B-3vn9A: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	LEU A 59 LYS A 82 ILE A 127 MET A 132 VAL A 185	None ANK A 401 (-2.4A) None None None	1.17A	3cs9C-3vn9A: 21.4	3cs9C-3vn9A: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3CS9_C_NILC600_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 9	LEU A 59 VAL A 67 LYS A 82 VAL A 113 ILE A 127 MET A 132	None ANK A 401 (-4.3A) ANK A 401 (-2.4A) None None None	1.13A	3cs9C-3vn9A: 21.4	3cs9C-3vn9A: 26.75
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3IK3_B_0LIB2_2 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 7	LEU A 59 LYS A 82 ILE A 127 MET A 132	None ANK A 401 (-2.4A) None None	0.76A	3ik3B-3vn9A: 21.9	3ik3B-3vn9A: 25.95
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MS9_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LYS A 82 VAL A 113 ILE A 127 MET A 132	ANK A 401 (-2.4A) None None None	1.03A	3ms9A-3vn9A: 21.7	3ms9A-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_A_STIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LYS A 82 VAL A 113 ILE A 127 MET A 132	ANK A 401 (-2.4A) None None None	1.03A	3mssA-3vn9A: 21.9	3mssA-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_C_STIC1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LYS A 82 VAL A 113 ILE A 127 MET A 132	ANK A 401 (-2.4A) None None None	1.07A	3mssC-3vn9A: 21.9	3mssC-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3MSS_D_STID1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 6	VAL A 67 LYS A 82 VAL A 113 ILE A 127 MET A 132	ANK A 401 (-4.3A) ANK A 401 (-2.4A) None None None	1.14A	3mssD-3vn9A: 22.0	3mssD-3vn9A: 26.81
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	LEU A 59 LYS A 82 ILE A 127 MET A 132 LEU A 186	None ANK A 401 (-2.4A) None None ANK A 401 ( 4.9A)	0.98A	3oxzA-3vn9A: 8.3	3oxzA-3vn9A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3OXZ_A_0LIA1_2 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	LEU A 59 LYS A 82 ILE A 127 MET A 132 VAL A 185	None ANK A 401 (-2.4A) None None None	0.96A	3oxzA-3vn9A: 8.3	3oxzA-3vn9A: 26.25
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UE4_A_DB8A601_1 (TYROSINE-PROTEIN KINASE ABL1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 ALA A 80 LYS A 82 VAL A 113 ILE A 127 MET A 132 LEU A 186	None ANK A 401 (-3.0A) ANK A 401 (-2.4A) None None None ANK A 401 ( 4.9A)	0.93A	3ue4A-3vn9A: 22.5	3ue4A-3vn9A: 25.29
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 ALA A 80 LYS A 82 MET A 129 LEU A 131 MET A 132 LEU A 186	None ANK A 401 (-3.0A) ANK A 401 (-2.4A) ANK A 401 (-3.7A) None None ANK A 401 ( 4.9A)	0.85A	3ug2A-3vn9A: 21.0	3ug2A-3vn9A: 26.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3UG2_A_IREA1_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 VAL A 67 ALA A 80 LYS A 82 LEU A 131 MET A 132 LEU A 186	None ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-2.4A) None None ANK A 401 ( 4.9A)	0.78A	3ug2A-3vn9A: 21.0	3ug2A-3vn9A: 26.93
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LYS A 82 ILE A 127 MET A 129 ASP A 179 LYS A 181 ASN A 184 ASP A 197	ANK A 401 (-2.4A) None ANK A 401 (-3.7A) ANK A 401 (-3.7A) ANK A 401 (-2.5A) ANK A 401 ( 2.7A) MG A 402 ( 2.8A)	0.75A	4an2A-3vn9A: 33.7	4an2A-3vn9A: 39.17
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4AN2_A_EUIA1382_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LYS A 82 MET A 129 ASP A 179 LYS A 181 ASN A 184 ASP A 197 GLY A 199	ANK A 401 (-2.4A) ANK A 401 (-3.7A) ANK A 401 (-3.7A) ANK A 401 (-2.5A) ANK A 401 ( 2.7A) MG A 402 ( 2.8A) None	0.80A	4an2A-3vn9A: 33.7	4an2A-3vn9A: 39.17
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4ANS_A_VGHA9000_1 (ALK TYROSINE KINASE RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 9	LEU A 59 VAL A 67 ALA A 80 MET A 129 MET A 132 LEU A 186	None ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None ANK A 401 ( 4.9A)	0.69A	4ansA-3vn9A: 21.6	4ansA-3vn9A: 26.80
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4CKI_A_ADNA2022_1 (PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 11	LEU A 59 GLY A 60 VAL A 67 ALA A 80 SER A 135 LEU A 186	None ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A)	0.87A	4ckiA-3vn9A: 22.1	4ckiA-3vn9A: 24.18
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	4LMN_A_EUIA503_1 (DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 12	LYS A 82 ILE A 127 MET A 129 ASN A 184 ASP A 197	ANK A 401 (-2.4A) None ANK A 401 (-3.7A) ANK A 401 ( 2.7A) MG A 402 ( 2.8A)	0.68A	4lmnA-3vn9A: 33.4	4lmnA-3vn9A: 35.32
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LEU A 59 ALA A 80 MET A 129 MET A 132	None ANK A 401 (-3.0A) ANK A 401 (-3.7A) None	0.66A	4wboC-3vn9A: 7.3	4wboC-3vn9A: 23.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4WBO_C_ANWC601_0 (RHODOPSIN KINASE)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	LEU A 59 ALA A 80 MET A 132 LEU A 186	None ANK A 401 (-3.0A) None ANK A 401 ( 4.9A)	0.86A	4wboC-3vn9A: 7.3	4wboC-3vn9A: 23.96
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XOY_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	ALA A 80 LEU A 131 MET A 132 LEU A 186	ANK A 401 (-3.0A) None None ANK A 401 ( 4.9A)	0.44A	4xoyA-3vn9A: 21.2	4xoyA-3vn9A: 25.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4XP3_A_DX4A401_0 (MITOGEN-ACTIVATED PROTEIN KINASE 1)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 6	ALA A 80 LEU A 131 MET A 132 LEU A 186	ANK A 401 (-3.0A) None None ANK A 401 ( 4.9A)	0.41A	4xp3A-3vn9A: 21.5	4xp3A-3vn9A: 25.76
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5H2U_B_1N1B501_1 (PROTEIN-TYROSINE KINASE 6)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 VAL A 67 ALA A 80 ILE A 127 LEU A 131 LEU A 186 ASP A 197	None ANK A 401 (-4.3A) ANK A 401 (-3.0A) None None ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.85A	5h2uB-3vn9A: 19.3	5h2uB-3vn9A: 24.71
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5J5X_B_AZ1B2_1 (CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA 47P-AZ1-DAL-DAR-DAR- DAR-DAR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 7	GLY A 60 GLY A 62 VAL A 67 LYS A 82 ASP A 197	ANK A 401 (-3.4A) ANK A 401 ( 4.9A) ANK A 401 (-4.3A) ANK A 401 (-2.4A) MG A 402 ( 2.8A)	1.04A	5j5xA-3vn9A: 17.5	5j5xA-3vn9A: 26.42
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_B_ADNB401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	GLY A 60 VAL A 67 ALA A 80 MET A 129 MET A 132	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None	0.49A	5lw1B-3vn9A: 21.2	5lw1B-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_E_ADNE401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 10	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 131 MET A 132	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None None	0.58A	5lw1E-3vn9A: 20.8	5lw1E-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_H_ADNH401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 9	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 131 MET A 132	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) None None	0.60A	5lw1H-3vn9A: 21.1	5lw1H-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5LW1_H_ADNH401_1 (MITOGEN-ACTIVATED PROTEIN KINASE 8)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	5 / 9	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 186	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A)	1.03A	5lw1H-3vn9A: 21.1	5lw1H-3vn9A: 13.82
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5VCY_A_DB8A401_2 (MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	4 / 4	VAL A 113 LEU A 131 ASN A 184 ASP A 197	None None ANK A 401 ( 2.7A) MG A 402 ( 2.8A)	1.19A	5vcyA-3vn9A: 22.4	5vcyA-3vn9A: 27.40
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 GLY A 60 ALA A 80 LYS A 82 MET A 129 LEU A 186 ASP A 197	None ANK A 401 (-3.4A) ANK A 401 (-3.0A) ANK A 401 (-2.4A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.96A	5yu9A-3vn9A: 24.0	5yu9A-3vn9A: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_A_1E8A1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	7 / 12	LEU A 59 GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 186 ASP A 197	None ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.80A	5yu9A-3vn9A: 24.0	5yu9A-3vn9A: 12.54
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5YU9_B_1E8B1101_1 (EPIDERMAL GROWTH FACTOR RECEPTOR)	3vn9	DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6 (Homo sapiens)	6 / 12	GLY A 60 VAL A 67 ALA A 80 MET A 129 LEU A 186 ASP A 197	ANK A 401 (-3.4A) ANK A 401 (-4.3A) ANK A 401 (-3.0A) ANK A 401 (-3.7A) ANK A 401 ( 4.9A) MG A 402 ( 2.8A)	0.80A	5yu9B-3vn9A: 24.0	5yu9B-3vn9A: 12.54

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1IEP_A_STIA201_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LYS A  82;VAL A 113;ILE A 127;MET A 132","ANK A 401 (-2.4A);None;None;None","1.02A","1iepA-3vn9A:21.5",null],["1IEP_B_STIB202_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"VAL A 113;MET A 132;ARG A 178;LEU A 186","None;None;None;ANK A 401 ( 4.9A)","0.85A","1iepB-3vn9A:21.7","1iepA-3vn9A:26.81"],["1OPJ_B_STIB4_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;LYS A  82;ILE A 127;MET A 132","None;ANK A 401 (-2.4A);None;None","0.82A","1opjB-3vn9A:21.1","1iepB-3vn9A:26.81"],["2EVA_A_ADNA498_1","TAK1 KINASE - TAB1 CHIMERA FUSION PROTEIN","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"GLY A  60;VAL A  67;ALA A  80;MET A 129;SER A 135;LEU A 186;ASP A 197","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.77A","2evaA-3vn9A:23.9","1opjB-3vn9A:26.81"],["2HYY_A_STIA600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;LYS A  82;VAL A 113;ILE A 127","None;ANK A 401 (-2.4A);None;None","0.84A","2hyyA-3vn9A:22.1","2evaA-3vn9A:25.48"],["2HYY_C_STIC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;LYS A  82;ILE A 127;MET A 132","None;ANK A 401 (-2.4A);None;None","0.82A","2hyyC-3vn9A:22.2","2hyyA-3vn9A:26.15"],["2HYY_D_STID600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;LYS A  82;VAL A 113;MET A 132","None;ANK A 401 (-2.4A);None;None","1.18A","2hyyD-3vn9A:22.1","2hyyC-3vn9A:26.15"],["2J9C_A_ACTA1122_0","HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"SER A 201;SER A 207;LYS A 210;LYS A 181","ANK A 401 (-3.6A);None;ANK A 401 (-3.0A);ANK A 401 (-2.5A)","1.48A","2j9cA-3vn9A:2.0;2j9cB-3vn9A:undetectable;2j9cC-3vn9A:2.0","2hyyD-3vn9A:26.15"],["2J9C_A_ACTA1122_0","HYPOTHETICAL NITROGEN REGULATORY PII-LIKE PROTEIN MJ0059","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"SER A 207;LYS A 210;LYS A 181;SER A 201","None;ANK A 401 (-3.0A);ANK A 401 (-2.5A);ANK A 401 (-3.6A)","1.44A","2j9cA-3vn9A:2.0;2j9cB-3vn9A:undetectable;2j9cC-3vn9A:2.0","2j9cA-3vn9A:18.13;2j9cB-3vn9A:18.13;2j9cC-3vn9A:18.13"],["2Y7J_B_B49B1294_1","PHOSPHORYLASE B KINASE GAMMA CATALYTIC CHAIN, TESTIS\/LIVER ISOFORM","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"VAL A  67;ALA A  80;LEU A 131;MET A 132;LEU A 186;ASP A 197","ANK A 401 (-4.3A);ANK A 401 (-3.0A);None;None;ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.78A","2y7jB-3vn9A:24.1","2j9cA-3vn9A:18.13;2j9cB-3vn9A:18.13;2j9cC-3vn9A:18.13"],["3AOX_A_EMHA901_1","ALK TYROSINE KINASE RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"LEU A  59;ALA A  80;VAL A 113;LEU A 131;MET A 132;LEU A 186","None;ANK A 401 (-3.0A);None;None;None;ANK A 401 ( 4.9A)","0.64A","3aoxA-3vn9A:21.5","2y7jB-3vn9A:24.60"],["3CS9_A_NILA600_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LEU A  59;VAL A  67;LYS A  82;VAL A 113;ILE A 127","None;ANK A 401 (-4.3A);ANK A 401 (-2.4A);None;None","0.68A","3cs9A-3vn9A:21.9","3aoxA-3vn9A:26.24"],["3CS9_B_NILB600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LEU A  59;VAL A  67;LYS A  82;VAL A 113;ILE A 127","None;ANK A 401 (-4.3A);ANK A 401 (-2.4A);None;None","0.72A","3cs9B-3vn9A:22.0","3cs9A-3vn9A:26.75"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LEU A  59;LYS A  82;ILE A 127;MET A 132;VAL A 185","None;ANK A 401 (-2.4A);None;None;None","1.17A","3cs9C-3vn9A:21.4","3cs9B-3vn9A:26.75"],["3CS9_C_NILC600_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"LEU A  59;VAL A  67;LYS A  82;VAL A 113;ILE A 127;MET A 132","None;ANK A 401 (-4.3A);ANK A 401 (-2.4A);None;None;None","1.13A","3cs9C-3vn9A:21.4","3cs9C-3vn9A:26.75"],["3IK3_B_0LIB2_2","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;LYS A  82;ILE A 127;MET A 132","None;ANK A 401 (-2.4A);None;None","0.76A","3ik3B-3vn9A:21.9","3cs9C-3vn9A:26.75"],["3MS9_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LYS A  82;VAL A 113;ILE A 127;MET A 132","ANK A 401 (-2.4A);None;None;None","1.03A","3ms9A-3vn9A:21.7","3ik3B-3vn9A:25.95"],["3MSS_A_STIA1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LYS A  82;VAL A 113;ILE A 127;MET A 132","ANK A 401 (-2.4A);None;None;None","1.03A","3mssA-3vn9A:21.9","3ms9A-3vn9A:26.81"],["3MSS_C_STIC1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LYS A  82;VAL A 113;ILE A 127;MET A 132","ANK A 401 (-2.4A);None;None;None","1.07A","3mssC-3vn9A:21.9","3mssA-3vn9A:26.81"],["3MSS_D_STID1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"VAL A  67;LYS A  82;VAL A 113;ILE A 127;MET A 132","ANK A 401 (-4.3A);ANK A 401 (-2.4A);None;None;None","1.14A","3mssD-3vn9A:22.0","3mssC-3vn9A:26.81"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LEU A  59;LYS A  82;ILE A 127;MET A 132;LEU A 186","None;ANK A 401 (-2.4A);None;None;ANK A 401 ( 4.9A)","0.98A","3oxzA-3vn9A:8.3","3mssD-3vn9A:26.81"],["3OXZ_A_0LIA1_2","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LEU A  59;LYS A  82;ILE A 127;MET A 132;VAL A 185","None;ANK A 401 (-2.4A);None;None;None","0.96A","3oxzA-3vn9A:8.3","3oxzA-3vn9A:26.25"],["3UE4_A_DB8A601_1","TYROSINE-PROTEIN KINASE ABL1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;ALA A  80;LYS A  82;VAL A 113;ILE A 127;MET A 132;LEU A 186","None;ANK A 401 (-3.0A);ANK A 401 (-2.4A);None;None;None;ANK A 401 ( 4.9A)","0.93A","3ue4A-3vn9A:22.5","3oxzA-3vn9A:26.25"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;ALA A  80;LYS A  82;MET A 129;LEU A 131;MET A 132;LEU A 186","None;ANK A 401 (-3.0A);ANK A 401 (-2.4A);ANK A 401 (-3.7A);None;None;ANK A 401 ( 4.9A)","0.85A","3ug2A-3vn9A:21.0","3ue4A-3vn9A:25.29"],["3UG2_A_IREA1_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;VAL A  67;ALA A  80;LYS A  82;LEU A 131;MET A 132;LEU A 186","None;ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-2.4A);None;None;ANK A 401 ( 4.9A)","0.78A","3ug2A-3vn9A:21.0","3ug2A-3vn9A:26.93"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LYS A  82;ILE A 127;MET A 129;ASP A 179;LYS A 181;ASN A 184;ASP A 197","ANK A 401 (-2.4A);None;ANK A 401 (-3.7A);ANK A 401 (-3.7A);ANK A 401 (-2.5A);ANK A 401 ( 2.7A); MG A 402 ( 2.8A)","0.75A","4an2A-3vn9A:33.7","3ug2A-3vn9A:26.93"],["4AN2_A_EUIA1382_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LYS A  82;MET A 129;ASP A 179;LYS A 181;ASN A 184;ASP A 197;GLY A 199","ANK A 401 (-2.4A);ANK A 401 (-3.7A);ANK A 401 (-3.7A);ANK A 401 (-2.5A);ANK A 401 ( 2.7A); MG A 402 ( 2.8A);None","0.80A","4an2A-3vn9A:33.7","4an2A-3vn9A:39.17"],["4ANS_A_VGHA9000_1","ALK TYROSINE KINASE RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"LEU A  59;VAL A  67;ALA A  80;MET A 129;MET A 132;LEU A 186","None;ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None;ANK A 401 ( 4.9A)","0.69A","4ansA-3vn9A:21.6","4an2A-3vn9A:39.17"],["4CKI_A_ADNA2022_1","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"LEU A  59;GLY A  60;VAL A  67;ALA A  80;SER A 135;LEU A 186","None;ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A)","0.87A","4ckiA-3vn9A:22.1","4ansA-3vn9A:26.80"],["4LMN_A_EUIA503_1","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"LYS A  82;ILE A 127;MET A 129;ASN A 184;ASP A 197","ANK A 401 (-2.4A);None;ANK A 401 (-3.7A);ANK A 401 ( 2.7A); MG A 402 ( 2.8A)","0.68A","4lmnA-3vn9A:33.4","4ckiA-3vn9A:24.18"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;ALA A  80;MET A 129;MET A 132","None;ANK A 401 (-3.0A);ANK A 401 (-3.7A);None","0.66A","4wboC-3vn9A:7.3","4lmnA-3vn9A:35.32"],["4WBO_C_ANWC601_0","RHODOPSIN KINASE","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"LEU A  59;ALA A  80;MET A 132;LEU A 186","None;ANK A 401 (-3.0A);None;ANK A 401 ( 4.9A)","0.86A","4wboC-3vn9A:7.3","4wboC-3vn9A:23.96"],["4XOY_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"ALA A  80;LEU A 131;MET A 132;LEU A 186","ANK A 401 (-3.0A);None;None;ANK A 401 ( 4.9A)","0.44A","4xoyA-3vn9A:21.2","4wboC-3vn9A:23.96"],["4XP3_A_DX4A401_0","MITOGEN-ACTIVATED PROTEIN KINASE 1","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"ALA A  80;LEU A 131;MET A 132;LEU A 186","ANK A 401 (-3.0A);None;None;ANK A 401 ( 4.9A)","0.41A","4xp3A-3vn9A:21.5","4xoyA-3vn9A:25.76"],["5H2U_B_1N1B501_1","PROTEIN-TYROSINE KINASE 6","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;VAL A  67;ALA A  80;ILE A 127;LEU A 131;LEU A 186;ASP A 197","None;ANK A 401 (-4.3A);ANK A 401 (-3.0A);None;None;ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.85A","5h2uB-3vn9A:19.3","4xp3A-3vn9A:25.76"],["5J5X_B_AZ1B2_1","CAMP-DEPENDENT PROTEIN KINASE CATALYTIC SUBUNIT ALPHA;47P-AZ1-DAL-DAR-DAR-DAR-DAR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"GLY A  60;GLY A  62;VAL A  67;LYS A  82;ASP A 197","ANK A 401 (-3.4A);ANK A 401 ( 4.9A);ANK A 401 (-4.3A);ANK A 401 (-2.4A); MG A 402 ( 2.8A)","1.04A","5j5xA-3vn9A:17.5","5h2uB-3vn9A:24.71"],["5LW1_B_ADNB401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"GLY A  60;VAL A  67;ALA A  80;MET A 129;MET A 132","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None","0.49A","5lw1B-3vn9A:21.2","5j5xA-3vn9A:26.42"],["5LW1_E_ADNE401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 131;MET A 132","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None;None","0.58A","5lw1E-3vn9A:20.8","5lw1B-3vn9A:13.82"],["5LW1_H_ADNH401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 131;MET A 132","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);None;None","0.60A","5lw1H-3vn9A:21.1","5lw1E-3vn9A:13.82"],["5LW1_H_ADNH401_1","MITOGEN-ACTIVATED PROTEIN KINASE 8","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",5,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 186","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A)","1.03A","5lw1H-3vn9A:21.1","5lw1H-3vn9A:13.82"],["5VCY_A_DB8A401_2","MEMBRANE-ASSOCIATED TYROSINE- AND THREONINE-SPECIFIC CDC2-INHIBITORY KINASE","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",4,"VAL A 113;LEU A 131;ASN A 184;ASP A 197","None;None;ANK A 401 ( 2.7A); MG A 402 ( 2.8A)","1.19A","5vcyA-3vn9A:22.4","5lw1H-3vn9A:13.82"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;GLY A  60;ALA A  80;LYS A  82;MET A 129;LEU A 186;ASP A 197","None;ANK A 401 (-3.4A);ANK A 401 (-3.0A);ANK A 401 (-2.4A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.96A","5yu9A-3vn9A:24.0","5vcyA-3vn9A:27.40"],["5YU9_A_1E8A1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",7,"LEU A  59;GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 186;ASP A 197","None;ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.80A","5yu9A-3vn9A:24.0","5yu9A-3vn9A:12.54"],["5YU9_B_1E8B1101_1","EPIDERMAL GROWTH FACTOR RECEPTOR","3vn9","DUAL SPECIFICITY MITOGEN-ACTIVATED PROTEIN KINASE KINASE 6","Homo sapiens",6,"GLY A  60;VAL A  67;ALA A  80;MET A 129;LEU A 186;ASP A 197","ANK A 401 (-3.4A);ANK A 401 (-4.3A);ANK A 401 (-3.0A);ANK A 401 (-3.7A);ANK A 401 ( 4.9A); MG A 402 ( 2.8A)","0.80A","5yu9B-3vn9A:24.0","5yu9A-3vn9A:12.54"]]